Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Biotechnology company presents new data on cancer drug candidates
May 19th, 2005
Myriad Genetics, Inc., (MYGN) announced that it presented data on its cancer drug candidate MPC-6827 and the antitumor activity of drug candidate MPC-2130 during the American Association for Cancer Research annual meeting. The first of four Myriad presentations at the meeting was entitled, "Antitumor Activity of MPC-2130 in Human Ovarian and Prostate Tumor Xenografts in Athymic Nude Mice." The presentation described the ability of MPC-2130 to inhibit the growth of blood and solid tumors such as lymphomas, ovarian cancers and prostate cancers, in mouse cancer models. In addition, in vitro studies showed that MPC-2130 was not a substrate for MDR pumps...
Source: Women's Health Weekly (2005-05-19)
|
